2023 Highlights: Partnerships and Innovations in Genomics

As 2023 comes to a close, the Helix team is honored to have accomplished so much this past year in service to health systems, public health organizations, and life sciences companies across the U.S. We share below some of the pivotable advancements we made that are moving the industry forward:

A few of our key highlights:

Expanding Collaborations
We welcomed new partners who share a vision of weaving genomics into the fabric of healthcare, including: St Luke’s University Health Network, Nebraska Medicine, Cone Health and Sanford Health. These progressive health systems join our growing list of partners in leading the industry with precision health, and each of their programs made significant progress in sequencing their communities. Mayo Clinic celebrated their 100,000th enrollee into their Tapestry program in September, 18 months ahead of schedule, while several others launched their programs at record speed (~3 months) or saw increased growth in their monthly enrollment. 

Growing our Commitment to Health Equity
Our programs also increased their efforts towards capturing a more diverse participant population, whether through amplifying Community Advisory Board voices, sharing heartfelt patient testimonials, or heading directly into communities to better understand and address concerns around privacy and security. We will be launching a Health Equity Subcommittee across our health system network to continue our combined focus on equitable individual and community care, and are looking forward to seeing the impact in 2024 and beyond.

Building Our Clinico-Genomic Dataset
With the onboarding of new health system partners, we are rapidly building clinico-genomic cohorts to support life science discoveries and development in key therapeutic areas like cardiometabolic conditions, neuro- degenerative disorders and immune-mediated inflammatory diseases. We completed our first joint pharma publication with Pfizer this year that studied the clinical impact of SARS-CoV-2 using real-world evidence studies to measure rebound rates and identify gaps in antiviral treatments (paper accepted at Clinical Infectious Diseases) that may prevent hospitalizations across the nation by upwards of 70%.

Accelerating Genomics Innovation
We continued to break new ground in genomics, contributing significantly to our collective understanding of precision medicine. Key findings included new analyses performed with our health system partners to combine exome sequencing with EMRs and uncover more precise methods for stratifying patients for their risk of kidney disease, breast cancer and Type 2 diabetes that take into account their genetic profiles. Our unique partnerships with health systems allow us to bring these findings directly to providers to improve patient health.

Celebrating the Helix Team
We were honored to see our company applauded for our accomplishments with the win of the Best in Class - Longevity Award at The Digital Health Hub Foundation and Digital Health Awards at HLTH this year, which recognizes companies transforming the way populations age in order to ensure better health for extended longevity. We believe genomics is essential information that every care provider should have at their fingertips in order to provide their patients precision care, and won’t stop until this belief is a reality.

From forging new partnerships to pioneering research, 2023 underscored our dedication to enhancing healthcare through genomics. We look forward to seeing how our efforts not only contribute to the scientific community but pave the way for more personalized, effective, and equitable healthcare solutions worldwide. If you’d like to get in touch with our team to learn more about these efforts and our vision for 2024, please reach out to us using the form below.

Happy Holidays!